nach oben

Cardiovascular Toxicology

Erschienen in:

01.03.2011

Values of Using QTc and N-Terminal Fragment of B-Type Natriuretic Peptide as Markers for Early Detection of Acute Antipsychotic Drugs-Induced Cardiotoxicity

verfasst von: Mohamed A. M. Khalaf, Tarek M. AbdelRahman, Mohamed F. Abbas

Erschienen in: Cardiovascular Toxicology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

We aimed at studying the acute cardiotoxicity of the most commonly used antipsychotics in Egypt using QTc interval and NT-proBNP as markers for the early detection of such cases. Eighty-two admitted patients, at El-Minia PCC (period from 1-7-2005 to 30-6-2010), were classified into 3 groups: I: acute thioridazine overdose (n = 28), II: acute pimozide overdose (n = 23), and III: acute clozapine overdose (n = 31). Patients were investigated for NT-proBNP level and QTc on admission (day 0) and after 24 h (day 1). All the studied drugs had the ability to induce cardiotoxicity in the form of hypotension and dysrhythmias. Thioridazine and pimozide had potentially serious cardiotoxic effects than clozapine. NT-proBNP levels were elevated significantly in all groups on days 0 and 1 when compared with the reference value and a significant decrease in the same parameter on day 1 when compared with that of day 0 within the same group. QTc showed a significant prolongation in all studied groups on days 0 and 1, and there was a significant shortening of QTc on day 1 when compared with that of day 0 within the same group. A significant positive correlation of NT-proBNP level elevation with QTc prolongation was reported in all groups on days 0 and 1. Serious dysrhythmias were associated with QTc prolongation greater than 500 ms. And it was concluded that NT-proBNP, in adjunction with QTc measurement, may be a valuable and sensitive laboratory biomarker to predict cardiotoxicity of antipsychotic overdose. Larger multicenter studies are still needed to verify this possible relationship.

Baldessarini, R. J., & Tarazi, F. I. (2006). Pharmacotherapy of psychosis and mania. In L. L. Brunton et al. (Eds), Goodman & Gilman’s: The pharmacological basis of therapeutics, 11th ed. (Sec. II, Ch. 18, pp. 461–500). McGraw-Hill Co, Inc.

Yasue, H., Yoshimura, M., Sumida, H., Kikuta, K., Kugiyama, K., Jougasaki, M., et al. (1994). Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation, 90, 195–203.PubMed

Hammerer-Lercher, A., Puschendorf, B., & Mair, J. (2001). Cardiac natriuretic peptides: New laboratory parameters in heart failure patients. Clinical Laboratory, 47, 265–277.PubMed

de Lemos, J. A., McGuire, D. K., & Drazner, M. H. (2003). B-type natriuretic peptide in cardiovascular disease. Lancet, 362, 316–322.CrossRefPubMed

Bruneau, B. G., Piazza, L. A., & de Bold, A. J. (1997). BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. American Journal of Physiology, 273, 2678–2686.

Bibbins-Domingo, K., Gupta, R., Na, B., Wu, A. H. B., Schiller, N. B., & Whooley, M. A. (2007). N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA, 297, 169–176.CrossRefPubMed

Garson, A., Jr. (1993). How to measure the QT interval—What is normal? American Journal of Cardiology, 72, 14B–16B.CrossRefPubMed

Moss, A. J., & Robinson, J. L. (1992). The long QT syndrome: Genetic consideration. Trends in Cardiovascular Medicine, 2, 81–83.CrossRefPubMed

LaGrenade, L., Graham, D., & Trontell, A. (2001). Myocarditis and cardiomyopathy associated with clozapine use in the United States. New England Journal of Medicine, 345, 224–225.CrossRef

10.

Straus, S. M. J. M., Sturkenboom, M. C. J. M., Bleumink, G. S., Dieleman, J. P., van der Lei, J., de Graeff, P. A., et al. (2005). Non-cardiac QTc prolonging drugs and the risk of sudden cardiac death. European Heart Journal, 26, 2007–2012.CrossRefPubMed

11.

Straus, S. M. J. M., Bleumink, G. S., Dieleman, J. P., van der Lei, J., Jong, G. E., Kingma, J. H., et al. (2004). Antipsychotic and the risk of sudden cardiac death. Archives of Internal Medicine, 164, 1293–1297.CrossRefPubMed

12.

Gardner, D. M., Baldessarini, R. J., & Waraich, P. (2005). Modern antipsychotic drugs: A critical overview. CMAJ, 172, 1703–1711.PubMed

13.

Hennessy, S., Bilker, W. B., Knauss, J. S., Margolis, D. J., Kimmel, S. E., Reynolds, R. F., et al. (2002). Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: Cohort study using administrative data. BMJ, 325, 1070–1074.CrossRefPubMed

14.

Fayek, M., Kingsbury, S. J., Zada, J., & Simpson, G. M. (2001). Cardiac effects of antipsychotic medications. Psychiatric Services, 52(5), 607–609.CrossRefPubMed

15.

Vieweg, W. V. R., & Wood, M. A. (2004). Tricyclic antidepressants, QT interval prolongation and torsade de pointes. Psychosomatics, 45, 371–377.CrossRefPubMed

16.

Glassman, A. H., & Bigger, J. T. (2001). Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. American Journal of Psychiatry, 158, 1774–1782.CrossRefPubMed

17.

Daniel, D. G. (2003). Tolerability of ziprasidone: An expanding perspective. Journal of Clinical Psychology, 64(19), 40–49.

18.

Taylor, D. (2003). Ziprasidone in the management of schizophrenia: The QT interval issue in context. CNS Drugs, 17, 423–430.CrossRefPubMed

19.

Capel, M. M., Clobridge, M. G., & Henry, J. A. (2000). Overdose profiles of new antipsychotic agents. International Journal of Neuropsychopharmacology, 3, 51–54.CrossRefPubMed

20.

Reilly, J. G., Ayis, S. A., Ferrier, I. N., Jones, S. J., & Thomas, S. H. (2000). QTc interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet, 355, 1048–1052.CrossRefPubMed

21.

Thomas, S. H. L. (1994). Drugs, QT interval abnormalities, and ventricular arrhythmias. Adverse Drug Reactions and Toxicological Reviews, 13, 77–102.PubMed

22.

Mackin, P. (2008). Cardiac side effects of psychiatric drugs. Human Psychopharmacology, 23(1), 3–14.CrossRefPubMed

23.

Merrill, D. B., Dec, G. W., & Goff, D. C. (2005). Adverse cardiac effects associated with clozapine. Journal of Clinical Psychopharmacology, 25(1), 32–41.CrossRefPubMed

24.

Harrigan, E. P., Miceli, J. J., Anziano, R., Watsky, E., Reeves, K. R., Cutler, N. R., et al. (2004). A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. Journal of Clinical Psychopharmacology, 24(1), 62–69.CrossRefPubMed

25.

Ray, W. A., Meredith, S., Thapa, P. B., Meador, K. G., Hall, K., & Murray, K. T. (2001). Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry, 58, 1161–1167.CrossRefPubMed

26.

Antzelevitch, C., & Fish, J. M. (2006). Therapy for the Brugada syndrome. In R. Kass & C. E. Clancy (Eds.), Handbook of experimental pharmacology (pp. 305–330). New York: Springer.

27.

Fish, J. M., & Antzelevitch, C. (2004). Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm, 1, 210–217.CrossRefPubMed

28.

Kropp, S., Tountopoulou, A., Schneider, U., & Lichtinghagen, R. (2005). N-terminal fragment of B-type natriuretic peptide (NT-proBNP), a marker of cardiac safety during antipsychotic treatment. Annals of General Psychiatry, 4, 10.CrossRefPubMed

29.

Chan, D., & Ng, L. L. (2010). Biomarkers in acute myocardial infarction. BMC Medicine, 8, 34.CrossRefPubMed

30.

Thejus, J., & Francis, J. (2009). N-terminal pro-brain natriuretic peptide and atrial fibrillation. Indian Pacing and Electrophysiology Journal, 9(1), 1–4.PubMed

31.

Rademaker, M. T., & Richards, A. M. (2005). Cardiac natriuretic peptides for cardiac health. Clinical Science (London), 108(1), 23–36.CrossRef

32.

Richards, A. M., & Frampton, C. M. (2005). N-terminal-Pro-B–type natriuretic peptide: Universal marker of cardiovascular risk? Circulation, 112, 9–11.CrossRefPubMed

33.

Kragelund, C., Gronning, B., Kober, L., et al. (2005). N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. New England Journal of Medicine, 352, 666–675.CrossRefPubMed

34.

Charpentier, J., Luyt, C. E., Fulla, Y., et al. (2004). Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Critical Care Medicine, 32, 660–665.CrossRefPubMed

35.

Chua, G., & Kang-Hoe, L. (2004). Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Critical Care, 8, R248–R250.CrossRefPubMed

36.

Roch, A., Allardet-Servent, J., Michelet, P., et al. (2005). NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Critical Care Medicine, 33, 1001–1007.CrossRefPubMed

37.

Herrmann, Z., Uhl, W., Steinberg, H. W., & Dworschack, R. (2003). The influence of renal function on NT-proBNP levels in various disease groups. Clinical Laboratory, 49, 649–656.PubMed

38.

Ma, K. K., Ogawa, T., & de Bold, A. J. (2004). Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. Journal of Molecular and Cellular Cardiology, 36, 505–513.CrossRefPubMed

39.

Tomaru Ki, K., Arai, M., Yokoyama, T., et al. (2002). Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. Journal of Molecular and Cellular Cardiology, 34, 649–659.CrossRefPubMed

40.

Harada, E., Nakagawa, O., Yoshimura, M., et al. (1999). Effect of interleukin-1 beta on cardiac hypertrophy and production of natriuretic peptides in rat cardiocyte culture. Journal of Molecular and Cellular Cardiology, 31, 1997–2006.CrossRefPubMed

41.

Bochud, P. Y., & Calandra, T. (2003). Pathogenesis of sepsis: New concepts and implications for future treatment. BMJ, 326, 262–266.CrossRefPubMed

42.

Tuinenburg, A. E., Brundel, B. J., Van Gelder, I. C., Henning, R. H., Van Den Berg, M. P., Driessen, C., et al. (1999). Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation. Journal of Cardiovascular Electrophysiology, 10, 827–835.CrossRefPubMed

43.

Steinhoff, J. P., & Sheahan, R. G. (2005). Tachycardia-induced cardiomyopathy: Atrial fibrillation and congestive heart failure. American Journal of the Medical Sciences, 329, 25–28.CrossRefPubMed

44.

Reilly, J. G., Ayis, S. A., Ferrier, I. N., Jones, S. J., & Thomas, S. H. (2002). Thioridazine and sudden unexplained death in psychiatric in-patients. British Journal of Psychiatry, 180, 515–522.CrossRefPubMed

45.

Liperoti, R., Gambassi, G., Lapane, K. L., Chiang, C., Pedone, C., Mor, V., et al. (2005). Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Archives of Internal Medicine, 165(28), 696–701.CrossRefPubMed

46.

Januzzi, J. L. (2006). Natriuretic peptide testing: A window into the diagnosis and prognosis of heart failure. Cleveland Clinc Journal of Medicine, 73(2), 149–157.CrossRef

47.

Yeo, K. T., Wu, A. H., Apple, F. S., Kroll, M. H., Christenson, R. H., Lewandrowski, K. B., et al. (2003). Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clinica Chimica Acta, 338(1–2), 107–115.CrossRef

Titel: Values of Using QTc and N-Terminal Fragment of B-Type Natriuretic Peptide as Markers for Early Detection of Acute Antipsychotic Drugs-Induced Cardiotoxicity
verfasst von: Mohamed A. M. Khalaf
Tarek M. AbdelRahman
Mohamed F. Abbas
Publikationsdatum: 01.03.2011
Verlag: Humana Press Inc
Erschienen in: Cardiovascular Toxicology / Ausgabe 1/2011
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-010-9102-y

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Values of Using QTc and N-Terminal Fragment of B-Type Natriuretic Peptide as Markers for Early Detection of Acute Antipsychotic Drugs-Induced Cardiotoxicity

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Grape Seed Extract Alleviates High-Fat Diet-Induced Obesity and Heart Dysfunction by Preventing Cardiac Siderosis

A Combination of Melatonin and Alpha Lipoic Acid has Greater Cardioprotective Effect than Either of them Singly Against Cadmium-Induced Oxidative Damage

Mechanistic Clues in the Cardioprotective Effect of Terminalia Arjuna Bark Extract in Isoproterenol-Induced Chronic Heart Failure in Rats

Protective Effect of FK506 on Myocardial Ischemia/Reperfusion Injury by Suppression of CaN and ASK1 Signaling Circuitry

Preventive Effects of Vanillic Acid on Lipids, Bax, Bcl-2 and Myocardial Infarct Size on Isoproterenol-Induced Myocardial Infarcted Rats: A Biochemical and In Vitro Study

Erratum to: A Combination of Melatonin and Alpha Lipoic Acid has Greater Cardioprotective Effect than Either of them Singly Against Cadmium-Induced Oxidative Damage